+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Benefits of statin therapy in patients with special risks: coronary bypass surgery, stable coronary disease, and acute coronary syndromes



Benefits of statin therapy in patients with special risks: coronary bypass surgery, stable coronary disease, and acute coronary syndromes



Clinical Cardiology 26(4 Suppl 3): Iii13-8



Several major clinical studies have examined the impact of lipid lowering in patients with and without coronary heart disease and have demonstrated that lowering lipid levels can successfully and significantly delay the onset of cardiovascular events. Although epidemiologic studies and small clinical trials have suggested that more aggressive and sustained lowering of low-density lipoprotein cholesterol (LDL-C) to < 100 mg/dl (2.6 mmol/l) can result in reductions in cardiovascular events in these populations, reducing LDL-C to these concentrations has only recently been shown in larger clinical trials. However, few clinical trials have been conducted in patients with certain special high risks, such as those who have had a recent revascularization procedure or have experienced an acute coronary event. Three trials examined the short- and long-term clinical benefits of aggressive lipid lowering in patients who underwent coronary artery bypass surgery (Post-CABG), were candidates for angioplasty (AVERT), or were hospitalized for acute coronary syndromes (MIRACL).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048366765

Download citation: RISBibTeXText

PMID: 12708634

DOI: 10.1002/clc.4960261504


Related references

TCT-287 Comparison of Multivessel Percutaneous Coronary Intervention with Coronary Artery Bypass Graft Surgery for Patients with Severe Coronary Artery Disease Presenting with Non-ST-segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 70(18): B117-B118, 2017

Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 93(8): 914-921, 2007

The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. European Heart Journal 37(48): 3576-3584, 2016

Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Journal of Thoracic Disease 9(5): 1345-1352, 2017

Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 103(25): 3069-3074, 2001

Impact of Clopidogrel therapy on the timing of coronary artery bypass surgery in patients with acute coronary syndromes A nationwide survey. Circulation 106(19 Suppl.): II 414, November 5, 2002

Comparison of multivessel percutaneous coronary intervention and coronary artery bypass grafting in patients with severe coronary artery disease presenting with non-ST-segment elevation acute coronary syndromes. Kardiologia Polska 76(10): 1474-1481, 2018

In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment. Atherosclerosis 194(1): 189-195, 2006

Comparison of one-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease and acute coronary syndromes (from the CUSTOMIZE Registry). American Journal of Cardiology 108(3): 355-359, 2011

Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. European Heart Journal 27(4): 413-418, 2005

Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 94(6): 743-747, 2007

Health related quality of life after percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with acute coronary syndromes without ST-segment elevation. 12-month follow up. European Journal of Cardio-Thoracic Surgery 27(5): 882-886, 2005

Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes. Cochrane Database of Systematic Reviews 2005(1): Cd004588, 2005

Long-term cardiovascular outcomes in patients with chronic kidney disease undergoing coronary artery bypass graft surgery for acute coronary syndromes. Journal of the American Heart Association 3(2): E000707, 2014

Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis 30(2): 200-209, 2010